New Guidance from FDA to Accelerate COVID-19 Treatments

(RAPS, 5/12/20) The US Food and Drug Administration (FDA) on Monday evening issued two guidances intended to accelerate the development of products to treat or prevent coronavirus disease (COVID-19), laying out recommendations to help companies get to the investigational new drug application (IND) stage and clinical trial design considerations for later-stage studies.

Read more here.